Solid Biosciences Q3 net loss widens 18% to $53.95 million
SLDB•SLDB•SLDB•SLDB•Solid Biosciences’ third-quarter 2026 net loss widened 18% year over year to $53.95 million. The company reported $348.9 million in cash, cash equivalents and available-for-sale securities, with an expected operational runway into the first half of 2028.
Research and development expenses rose 12% to $43.6 million, while general and administrative expenses increased 53% to $14.06 million. Solid Biosciences expects its cash, cash equivalents and available-for-sale securities, totaling $348.9 million at September 30, to support operations into the first half of 2028.
A late-fourth-quarter 2026 FDA meeting will address a potential accelerated approval pathway for Duchenne gene therapy SGT-003. SGT-212 had no treatment-related serious adverse events among five FALCON participants through November 3, and initial data are expected in the first quarter of 2027.
